樂普醫療(300003.SZ):子公司MWN109片獲得藥物臨牀試驗批準通知書
格隆匯5月9日丨樂普醫療(300003.SZ)公佈,公司控股子公司上海民爲生物技術有限公司(簡稱“民爲生物”)收到國家藥品監督管理局(NMPA)覈準簽發的《藥物臨牀試驗批準通知書》,由民爲生物申報的MWN109片臨牀試驗申請獲得批準。公司自主研發的GLP-1/GIP/GCG活性脂肪酸鏈修飾多肽藥物MWN109片是在MWN109注射液基礎上開發的口服劑型,作用機理爲通過刺激胰島β細胞分泌胰島素,有效控制血糖,通過延緩胃排空和抑制胃酸分泌,增加飽腹感,減少能量攝入,同時通過促進脂肪分解,增加能量排空和基礎代謝,有效降低體重。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.